LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.
Latest Ratings for LVTX
DateFirmActionFromTo Nov 2021SVB LeerinkMaintainsOutperform Aug 2021SVB LeerinkMaintainsOutperform Apr 2021JefferiesInitiates Coverage OnBuy